Featured Research

from universities, journals, and other organizations

MGH Study Identifies New Inhibitor Of Tumor Angiogenesis And Growth

Date:
December 21, 1999
Source:
Massachusetts General Hospital
Summary:
A research team based at the Massachusetts General Hospital (MGH) has shown that a natural factor called thrombospondin-2 (TSP-2) inhibits the development of certain tumors in a mouse model by preventing the development of blood vessels, a process called angiogenesis. TSP-2 now joins a growing list of anti-angiogenesis factors being studied and in some instances tested as possible anti-cancer drugs.

A research team based at the Massachusetts General Hospital (MGH) has shown that a natural factor called thrombospondin-2 (TSP-2) inhibits the development of certain tumors in a mouse model by preventing the development of blood vessels, a process called angiogenesis. TSP-2 now joins a growing list of anti-angiogenesis factors being studied and in some instances tested as possible anti-cancer drugs. The report from the MGH Cutaneous Biology Research Center (CBRC) appears in the Dec. 21 issue of Proceedings of the National Academy of Sciences.

"We have found a natural factor that inhibits angiogenesis in normal tissues and, when reintroduced into tumor cells, stops tumor growth," says Michael Detmar, MD, who led the study. Detmar notes that some of the other anti-angiogenesis factors currently being studied do not appear to be involved in normal blood vessel development but instead are produced when other substances in the body break down. "We believe that TSP-2 is part of a natural protein system designed to prevent the development of malignant tumors," he adds.

TSP-2 is one of a group of proteins that help regulate the proliferation and development of several types of cells. It is structurally similar to thrombospondin-1 (TSP-1), a known angiogenesis inhibitor. Although the two proteins are produced at different times during development and in different tissues, both appear at high levels in developing blood vessels, suggesting an important role in the regulation of angiogenesis. While TSP-1 had previously been shown to inhibit angiogenesis and tumor growth, TSP-2's exact biological role had been unclear. The current study not only verifies TSP-2's activity in suppressing tumor growth and angiogenesis, it also shows that expression of both proteins completely stopped growth of the tumors studied in this project.

The researchers introduced TSP-2 DNA into cultured cells from human squamous cell carcinomas - tumors that do not normally produce TSP-2 - and injected the cells into the skin of immune deficient mice. As a control, another group of mice received injections of unaltered human squamous cell carcinoma cells. While the unaltered cells quickly grew into tumors, tumors from the cells induced to produce TSP-2 grew very slowly and also showed reduced angiogenesis.

The suppression of tumor growth resulting from TSP-2 production was significantly greater than that seen in earlier studies of the effect of TSP-1 production - 90 percent reduction in tumor growth versus 40 to 50 percent. In addition, squamous cell carcinoma cells into which genes for both TSP-2 and TSP-1 were introduced completely failed to develop into tumors.

While they are encouraged by the study results, the researchers stress that many questions need to be answered about TSP-2's possible role as a cancer-fighting agent. Among these are exactly how the protein operates on a molecular level and whether the same anti-tumor effect is seen with other types of cancer. The researchers already have found a similar effect in human malignant melanoma. Also required are practical methods of inducing TSP-2 production in tumor cells. Possible strategies may include gene therapy approaches, introduction of small molecules that stimulate secretion of TSP-2, or bio-engineered implants that could deliver the protein to the area of a tumor.

Supporters of this study include the National Cancer Institute, the National Institutes of Health and the American Cancer Society. The study's co-authors are first author Michael Streit, MD, Lucia Riccardi, Paula Velasco, and Thomas Hawinghorst, MD, of the MGH CBRC; Lawrence Brown, MD, of Beth Israel Deaconess Medical Center; and Paul Bornstein, MD, of the University of Washington in Seattle.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts General Hospital. "MGH Study Identifies New Inhibitor Of Tumor Angiogenesis And Growth." ScienceDaily. ScienceDaily, 21 December 1999. <www.sciencedaily.com/releases/1999/12/991221081010.htm>.
Massachusetts General Hospital. (1999, December 21). MGH Study Identifies New Inhibitor Of Tumor Angiogenesis And Growth. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/1999/12/991221081010.htm
Massachusetts General Hospital. "MGH Study Identifies New Inhibitor Of Tumor Angiogenesis And Growth." ScienceDaily. www.sciencedaily.com/releases/1999/12/991221081010.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Costs Keep Mounting

Ebola Costs Keep Mounting

Reuters - Business Video Online (Sep. 23, 2014) The WHO has warned up to 20,000 people could be infected with Ebola over the next few weeks. As Sonia Legg reports, the implications for the West African countries suffering from the disease are huge. Video provided by Reuters
Powered by NewsLook.com
Ebola Cases Could Reach 1.4 Million Within 4 Months

Ebola Cases Could Reach 1.4 Million Within 4 Months

Newsy (Sep. 23, 2014) Health officials warn that without further intervention, the number of Ebola cases in Liberia and Sierra Leone could reach 1.4 million by January. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Cases to Triple in Weeks Without Drastic Action

WHO: Ebola Cases to Triple in Weeks Without Drastic Action

AFP (Sep. 23, 2014) The number of Ebola infections will triple to 20,000 by November, soaring by thousands every week if efforts to stop the outbreak are not stepped up radically, the WHO warned in a study on Tuesday. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
5 Ways Men Can Prevent Most Heart Attacks

5 Ways Men Can Prevent Most Heart Attacks

Newsy (Sep. 23, 2014) No surprise here: A recent study says men can reduce their risk of heart attack by maintaining a healthy lifestyle, which includes daily exercise. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins